Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'FLUPHENAZINE DECANOATE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 67 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wiedemann, G; Hahlweg, K; Muller, U; Feinstein, E; Hank, G; Dose, M
      Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    2. Gaebel, W
      Strategies of long-term medication in schizophrenia

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    3. Larsen, SW; Rinvar, E; Svendsen, O; Lykkesfeldt, J; Friis, GJ; Larsen, C
      Determination of the disappearance rate of iodine-125 labelled oils from the injection site after intramuscular and subcutaneous administration to pigs

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    4. Larsen, SW; Thomsen, AE; Rinvar, E; Friis, GJ; Larsen, C
      Effect of drug lipophilicity on in vitro release rate from oil vehicles using nicotinic acid esters as model prodrug derivatives

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    5. Gaertner, I; Gaertner, HJ; Vonthein, R; Dietz, K
      Therapeutic drug monitoring of clozapine in relapse prevention: A five-year prospective study

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    6. Allison, DB; Casey, DE
      Antipsychotic-induced weight gain: A review of the literature

      JOURNAL OF CLINICAL PSYCHIATRY
    7. Bosveld-van Haandel, LJM; Slooff, CJ; van den Bosch, RJ
      Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments

      ACTA PSYCHIATRICA SCANDINAVICA
    8. Hausmann, A; Fleischhacker, WW
      Depression in patients with schizophrenia - Prevalence, and diagnostic andtreatment considerations

      CNS DRUGS
    9. Gaebel, W
      Long-term medication in schizophrenia

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    10. Kuhn, KU; Meyer, K; Maier, W
      Flupentixol - A partial atypical neuroleptic?

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    11. Al-Sughayir, MA
      Depot antipsychotics - Patient characteristics and prescribing pattern

      SAUDI MEDICAL JOURNAL
    12. Siris, SG
      Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents

      AMERICAN JOURNAL OF PSYCHIATRY
    13. Young, JL; Spitz, RT; Hillbrand, M; Daneri, G
      Medication adherence failure in schizophrenia: A forensic review of rates,reasons, treatments, and prospects

      JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
    14. Marland, GR; Sharkey, V
      Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature

      JOURNAL OF ADVANCED NURSING
    15. Lister, S; Sorensen, SM; Hitchcock, JM; Wettstein, JG
      Effects of depot drug formulations in procedures used to evaluate antipsychotic activity in rodents

      DRUG DEVELOPMENT RESEARCH
    16. Kane, JM
      Management strategies for the treatment of schizophrenia

      JOURNAL OF CLINICAL PSYCHIATRY
    17. Kane, J
      Olanzapine in the long-term treatment of schizophrenia

      BRITISH JOURNAL OF PSYCHIATRY
    18. Kane, JM
      Pharmacologic treatment of schizophrenia

      BIOLOGICAL PSYCHIATRY
    19. Allison, DB; Mentore, JL; Heo, M; Chandler, LP; Cappelleri, JC; Infante, MC; Weiden, PJ
      Antipsychotic-induced weight gain: A comprehensive research synthesis

      AMERICAN JOURNAL OF PSYCHIATRY
    20. Baptista, T
      Body weight gain induced by antipsychotic drugs: mechanisms and management

      ACTA PSYCHIATRICA SCANDINAVICA
    21. KANE JM; AGUGLIA E; ALTAMURA AC; GUTIERREZ JLA; BRUNELLO N; FLEISCHHACKER WW; GAEBEL W; GERLACH J; GUELFI JD; KISSLING W; LAPIERRE YD; LINDSTROM E; MENDLEWICZ J; RACAGNI G; CARULLA LS; SCHOOLER NR
      GUIDELINES FOR DEPOT ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA

      European neuropsychopharmacology
    22. LUO JP; HUBBARD JW; MIDHA KK
      THE ROLES OF DEPOT INJECTION SITES AND PROXIMAL LYMPH-NODES IN THE PRESYSTEMIC ABSORPTION OF FLUPHENAZINE DECANOATE AND FLUPHENAZINE - EX-VIVO EXPERIMENTS IN RATS

      Pharmaceutical research
    23. Kinon, BJ
      The routine use of atypical antipsychotic agents: Maintenance treatment

      JOURNAL OF CLINICAL PSYCHIATRY
    24. LEVIN FR; EVANS SM; COOMARASWAMMY S; COLLINS ED; REGENT N; KLEBER HD
      FLUPENTIXOL TREATMENT FOR COCAINE ABUSERS WITH SCHIZOPHRENIA - A PILOT-STUDY

      The American journal of drug and alcohol abuse
    25. HOGARTY GE; ULRICH RF
      THE LIMITATIONS OF ANTIPSYCHOTIC MEDICATION ON SCHIZOPHRENIA RELAPSE AND ADJUSTMENT AND THE CONTRIBUTIONS OF PSYCHOSOCIAL TREATMENT

      Journal of Psychiatric Research
    26. LUO JP; HUBBARD JW; MIDHA KK
      SENSITIVE METHOD FOR THE SIMULTANEOUS MEASUREMENT OF FLUPHENAZINE DECANOATE AND FLUPHENAZINE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH COULOMETRIC DETECTION

      Journal of chromatography B. Biomedical sciences and applications
    27. AYUSOGUTIERREZ JL; DELRIOVEGA JM
      FACTORS INFLUENCING RELAPSE IN THE LONG-TERM COURSE OF SCHIZOPHRENIA

      Schizophrenia research
    28. SCHOOLER NR
      NEW-ANTIPSYCHOTIC MEDICATIONS - STRATEGIES FOR EVALUATION AND SELECTED FINDINGS

      Schizophrenia research
    29. LUO JP; HUBBARD JW; MIDHA KK
      STUDIES ON THE MECHANISM OF ABSORPTION OF DEPOT NEUROLEPTICS - FLUPHENAZINE DECANOATE IN SESAME OIL

      Pharmaceutical research
    30. MILLER R
      DOSE-RESPONSE RELATIONSHIPS FOR THE ANTIPSYCHOTIC EFFECTS AND PARKINSONIAN SIDE-EFFECTS OF TYPICAL NEUROLEPTIC DRUGS - PRACTICAL AND THEORETICAL IMPLICATIONS

      Progress in neuro-psychopharmacology & biological psychiatry
    31. VIGUERA AC; BALDESSARINI RJ; HEGARTY JD; VANKAMMEN DP; TOHEN M
      CLINICAL RISK FOLLOWING ABRUPT AND GRADUAL WITHDRAWAL OF MAINTENANCE NEUROLEPTIC TREATMENT

      Archives of general psychiatry
    32. DENCKER SJ; AXELSSON R
      OPTIMIZING THE USE OF DEPOT ANTIPSYCHOTICS

      CNS DRUGS
    33. MOLLER HJ
      REVIEW - TREATMENT OF SCHIZOPHRENIA - STATE-OF-THE-ART

      European archives of psychiatry and clinical neuroscience
    34. BARBUI C; SARACENO B
      LOW-DOSE NEUROLEPTIC THERAPY AND EXTRAPYRAMIDAL SIDE-EFFECTS IN SCHIZOPHRENIA - AN EFFECT SIZE ANALYSIS

      European psychiatry
    35. BARBUI C; SARACENO B; LIBERATI A; GARATTINI S
      LOW-DOSE NEUROLEPTIC THERAPY AND RELAPSE IN SCHIZOPHRENIA - METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS

      European psychiatry
    36. SCHOOLER NR; SEVERE JB; GLICK ID; HARGREAVES WA; KEITH SJ; WEIDEN P; MATTHEWS SM; SCHULTZ SC; ODBERT CL; KANE JM; LIEBERMAN JA; WOERNER M; BELLACK AS; SIMPSON GM; FRANCES AJ; JACOBS M; NINAN PT; MANCE RM; FALLOON IRH; MCGILL CW
      TRANSITION FROM ACUTE TO MAINTENANCE TREATMENT - PREDICTION OF STABILIZATION

      International clinical psychopharmacology
    37. JANICAK PG; SADEK HS
      PSYCHOPHARMACOTHERAPY FOR ACUTE AND RECURRENT PSYCHOTIC DISORDERS

      Psychiatric annals
    38. WEIDEN P; RAPKIN B; ZYGMUNT A; MOTT T; GOLDMAN D; FRANCES A
      POSTDISCHARGE MEDICATION COMPLIANCE OF INPATIENTS CONVERTED FROM AN ORAL TO A DEPOT NEUROLEPTIC REGIMEN

      Psychiatric services
    39. HUANG Y; HUBBARD JW; MIDHA KK
      THE ROLE OF THE LYMPHATIC-SYSTEM IN THE PRESYSTEMIC ABSORPTION OF FLUPHENAZINE AFTER INTRAMUSCULAR ADMINISTRATION OF FLUPHENAZINE DECANOATEIN RATS

      European journal of pharmaceutical sciences
    40. DIXON LB; LEHMAN AF; LEVINE J
      CONVENTIONAL ANTIPSYCHOTIC MEDICATIONS FOR SCHIZOPHRENIA

      Schizophrenia bulletin
    41. WEIDEN PJ; OLFSON M
      COST OF RELAPSE IN SCHIZOPHRENIA

      Schizophrenia bulletin
    42. HERESCOLEVY U; GREENBERG D; LERER B; DASBERG H; BROWN WA
      2-YEAR TRIAL OF MAINTENANCE NEUROLEPTIC DOSE REDUCTION IN SCHIZOPHRENIC OUT-PATIENTS - PREDICTORS OF RELAPSE

      Israel journal of psychiatry and related sciences
    43. LADER M
      WHAT IS RELAPSE IN SCHIZOPHRENIA

      International clinical psychopharmacology
    44. KANE JM
      DOSING ISSUES AND DEPOT MEDICATION IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA

      International clinical psychopharmacology
    45. MCFARLANE WR; LINK B; DUSHAY R; MARCHAL J; CRILLY J
      PSYCHOEDUCATIONAL MULTIPLE FAMILY GROUPS - 4-YEAR RELAPSE OUTCOME IN SCHIZOPHRENIA

      Family process
    46. HATCHER S
      DECISION-ANALYSIS IN PSYCHIATRY

      British Journal of Psychiatry
    47. HOGARTY GE; MCEVOY JP; ULRICH RF; DIBARRY AL; BARTONE P; COOLEY S; HAMMILL K; CARTER M; MUNETZ MR; PEREL J
      PHARMACOTHERAPY OF IMPAIRED AFFECT IN RECOVERING SCHIZOPHRENIC-PATIENTS

      Archives of general psychiatry
    48. MIDHA KK; HUBBARD JW; MARDER SR; MARSHALL BD; VANPUTTEN T
      IMPACT OF CLINICAL PHARMACOKINETICS ON NEUROLEPTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

      Journal of psychiatry & neuroscience
    49. FALLOON IRH; COVERDALE JH
      COGNITIVE-BEHAVIORAL FAMILY INTERVENTIONS FOR MAJOR MENTAL-DISORDERS

      Behaviour change
    50. MEISE U; KURZ M; FLEISCHHACKER WW
      ANTIPSYCHOTIC MAINTENANCE TREATMENT OF SCHIZOPHRENIA-PATIENTS - IS THERE A CONSENSUS

      Schizophrenia bulletin
    51. SOLGAARD T; KISTRUP K; AAESJORGENSEN T; GERLACH J
      ZUCLOPENTHIXOL DECANOATE IN MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS - MINIMUM EFFECTIVE DOSE AND CORRESPONDING SERUM LEVELS

      Pharmacopsychiatry
    52. DAVIS JM; METALON L; WATANABE MD; BLAKE L
      DEPOT ANTIPSYCHOTIC-DRUGS - PLACE IN THERAPY

      Drugs
    53. BIEGEL DE; MILLIGAN SE; PUTNAM PL; SONG LY
      PREDICTORS OF BURDEN AMONG LOWER SOCIOECONOMIC-STATUS CAREGIVERS OF PERSONS WITH CHRONIC MENTAL-ILLNESS

      Community mental health journal
    54. SIRIS SG; BERMANZOHN PC; MASON SE; SHUWALL MA
      MAINTENANCE IMIPRAMINE THERAPY FOR SECONDARY DEPRESSION IN SCHIZOPHRENIA - A CONTROLLED TRIAL

      Archives of general psychiatry
    55. BRANSGROVE LL; KELLY MW
      MOVEMENT-DISORDERS IN PATIENTS TREATED WITH LONG-ACTING INJECTABLE ANTIPSYCHOTIC-DRUGS

      American journal of hospital pharmacy
    56. MARDER SR
      THE ROLE OF DOSAGE AND PLASMA-LEVELS IN NEUROLEPTIC RELAPSE PREVENTION

      Acta psychiatrica Scandinavica
    57. DENCKER SJ; GIOS I; MARTENSSON E; NORDEN T; NYBERG G; PERSSON R; ROMAN G; STOCKMAN O; SVARD KO
      A LONG-TERM CROSS-OVER PHARMACOKINETIC STUDY COMPARING PERPHENAZINE DECANOATE AND HALOPERIDOL DECANOATE IN SCHIZOPHRENIC-PATIENTS

      Psychopharmacology
    58. CHINTALAPUDI M; KULHARA P; AVASTHI A
      POSTPSYCHOTIC DEPRESSION IN SCHIZOPHRENIA

      European archives of psychiatry and clinical neuroscience
    59. HOFMANN P; MELISCH B; ZAPOTOCZKY HG; KULHANEK F
      NEUROLEPTIC LOW-DOSE MAINTENANCE AND TARG ET MEDICATION STRATEGIES FOR CHRONIC-SCHIZOPHRENICS - A CRITICAL-REVIEW

      Fortschritte der Neurologie, Psychiatrie
    60. REMINGTON GJ; PRENDERGAST P; BEZCHLIBNYKBUTLER KZ
      DOSAGING PATTERNS IN SCHIZOPHRENIA WITH DEPOT, ORAL AND COMBINED NEUROLEPTIC THERAPY

      Canadian journal of psychiatry
    61. HERESCOLEVY U; BROM D; GREENBERG D
      SELF-REPORTED PRESCRIBING PRACTICES FOR SCHIZOPHRENIC-PATIENTS AMONG ISRAELI PSYCHIATRISTS

      Israel journal of psychiatry and related sciences
    62. MARDER SR; AMES D; WIRSHING WC; VANPUTTEN T
      SCHIZOPHRENIA

      The Psychiatric clinics of North America
    63. MIDHA KK; MARDER SR; JAWORSKI TJ; MCKAY G; HUBBARD JW; HAWES EM; VANPUTTEN T; WIRSHING WC; ARAVAGIRI M
      CLINICAL PERSPECTIVES OF SOME NEUROLEPTICS THROUGH DEVELOPMENT AND APPLICATION OF THEIR ASSAYS

      Therapeutic drug monitoring
    64. JANICAK PG
      THE RELEVANCE OF CLINICAL PHARMACOKINETICS AND THERAPEUTIC DRUG-MONITORING - ANTICONVULSANT MOOD STABILIZERS AND ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    65. HOGARTY GE
      PREVENTION OF RELAPSE IN CHRONIC-SCHIZOPHRENIC PATIENTS

      The Journal of clinical psychiatry
    66. DAVIS JM; KANE JM; MARDER SR; BRAUZER B; GIERL B; SCHOOLER N; CASEY DE; HASSAN M
      DOSE-RESPONSE OF PROPHYLACTIC ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    67. CORNELIUS JR; SOLOFF PH; PEREL JM; ULRICH RF
      CONTINUATION PHARMACOTHERAPY OF BORDERLINE PERSONALITY-DISORDER WITH HALOPERIDOL AND PHENELZINE

      The American journal of psychiatry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 04:06:19